摘要
目的探讨贝伐珠单抗联合奥沙利铂及卡培他滨对晚期结肠癌患者疗效、免疫功能及肿瘤标志物的影响。方法选择该院2018年1月至2021年1月收治的99例晚期结肠癌患者为研究对象。采用随机数字表法将患者分为两组,对照组50例患者采取奥沙利铂及卡培他滨治疗,观察组49例患者采取贝伐珠单抗联合奥沙利铂及卡培他滨治疗,比较两组患者疗效、治疗前后糖类抗原(CA)242及癌胚抗原(CEA)水平变化及白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)水平、T细胞亚群指标(CD3^(+)、CD4^(+))变化、不良反应发生情况,同时比较治疗前后患者生活质量量表(KPS)评分及视觉模拟疼痛评分(VAS评分)变化、治疗满意度。结果观察组总有效率(53.06%)高于对照组(32.00%),差异有统计学意义(P<0.05);观察组患者治疗后CA242、CEA、IL-6、IL-1β水平低于对照组(P<0.05);治疗后观察组CD3^(+)、CD4^(+)水平高于对照组(P<0.05);治疗后观察组KPS评分高于对照组,VAS评分低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组治疗满意度(91.84%)高于对照组(70.00%),差异有统计学意义(P<0.05)。结论贝伐珠单抗联合奥沙利铂及卡培他滨对晚期结肠癌患者疗效较好,对患者免疫功能、生活质量具有积极影响,患者恢复好,安全可靠,值得临床推广应用。
Objective To explore the effect of bevacizumab combined with oxaliplatin and capecitabine on efficacy,immune function and tumor markers in advanced colon cancer patients.Methods A total of 99 patients with advanced colon cancer who were admitted to the hospital from January 2018 to January 2021 were divided into two groups by random number table method.A total of 50 patients in the control group were treated with oxaliplatin and capecitabine,and 49 patients in the observation group were treated with bevacizumab combined with oxaliplatin and capecitabine.Curative effects,carbohydrate antigen 242(CA242),carcinoembryonic antigen(CEA),interleukin 6(IL-6),interleukin 1 beta(IL-1β)level change before and after the treatment,T cell subsets(CD3^(+),CD4^(+)),side effects,patients′quality of life scale before and after the treatment(KPS)score and visual analog score(VAS score)change,treatment satisfaction were analyzed.Results Compared with control group(32.00%),the effective rate of observation group(53.06%)was significantly higher(P<0.05).CA242,CEA,IL-6 and IL-1βlevels of observation group after treatment were significantly lower than that of control group(P<0.05).CD3^(+)and CD4^(+)levels of observation group after treatment were significantly higher than that of control group(P<0.05).KPS score of observation group after treatment was significantly higher than that of control group(P<0.05).VAS score of observation group after treatment was significantly lower than that of control group(P<0.05).The rates of side effects in two groups had no significant significance(P>0.05).The satisfaction rate of the observation group(91.84%)was significantly higher than that of the control group(70.00%),difference was statistically significant(P<0.05).Conclusion Bevacizumab combined with oxaliplatin and capecitabine has a good effect on advanced colon cancer patients,and has a positive effect on the immune function and quality of life of patients.Patients recover well,side effects can be alleviated,and it is safe and reliable,which is worthy of application.
作者
陶洪
吴福道
赵祥丽
付江萍
张小静
TAO Hong;WU Fudao;ZHAO Xiangli;FU Jiangping;ZHANG Xiaojing(Department of Oncology,Dazhou Central Hospital,Dazhou,Sichuan 635000,China)
出处
《国际检验医学杂志》
CAS
2022年第12期1500-1503,共4页
International Journal of Laboratory Medicine
关键词
结肠癌
贝伐珠单抗
奥沙利铂
卡培他滨
疗效
免疫功能
肿瘤标志物
advanced colon cancer
bevacizumab
oxaliplatin
capecitabine
curative effect
immune function
tumor marker
